FDA Warns Wild Arabic Herbs Over Cancer Claims for Herbal Product
FDA issued a warning letter to Wild Arabic Herbs after reviewing the company’s website and determining that its “Edral-17t” product was marketed as an unapproved new drug.
FDA cited claims that the product was a “Desert Herbs Formula for Prostate & Testicules [sic] Cancers” and was promoted for patients with prostate cancer, testicular malignancies, and other severe male reproductive conditions.
The agency also cited claims describing anticancer, antiproliferative, anti-metastatic, and selective cytotoxic effects, including statements that the product could inhibit uncontrolled cell division, prevent spread of malignant cells, and act against multiple cancer types.
FDA concluded that these claims established the product’s intended use as a drug. Because no approved FDA application was in effect for the product, FDA determined it was an unapproved new drug.
The firm was instructed to respond within 15 business days with corrective steps and measures to prevent recurrence.
MDP Perspective
This warning letter involves some of the highest-risk claim language in FDA enforcement: cancer treatment claims.
FDA has consistently treated cancer-related claims as a serious public health concern because patients may delay or avoid evidence-based medical care in favor of unapproved products.
For herbal, natural, supplement, and wellness companies, this letter is a clear warning. Claims involving cancer, metastasis, apoptosis, cytotoxicity, or disease treatment are not casual marketing language. They can create drug status immediately and invite FDA enforcement.
Links
Warning letter to Leading Edge Health, Inc.
FDA Issues 14 Warning Letters Targeting Online Unapproved Drug Sales
FDA Approves Retevmo for RET Fusion-Positive Solid Tumors
FDA Grants Full Approval to Retevmo for RET Fusion-Positive Metastatic Solid TumorsApproval expands precision medicine option for adults and children with advanced cancers The U.S. Food and Drug Administration (FDA) has granted traditional approval to Retevmo...
FDA Warning Letters Target Online Ketamine Sellers
Seven Warning Letters Signal Increased FDA Scrutiny The U.S. Food and Drug Administration (FDA) has launched a coordinated enforcement action against websites marketing unapproved ketamine-related drug products, issuing seven Warning Letters on July 7, 2026, to online...
FDA Warns Amazon for Unapproved Drugs Sold On Its Website
FDA Issues Warning Letter to Amazon for Unapproved Drug Products FDA issued a warning letter to Amazon.com, Inc. after purchasing and reviewing products sold through Amazon’s website and fulfilled through Amazon’s logistics network. The products identified were...
FDA Warns Leading Edge Health Over Unapproved New Drugs
FDA Warning Letter Targets Erectin Stimulating Gel and VigRX Delay Wipes FDA issued a warning letter to Leading Edge Health Inc. after reviewing the company’s website and determining that two sexual health products were being marketed as unapproved new drugs. The...
FDA Targets Online Marketing of Unapproved Drugs
FDA Issues 14 Warning Letters Targeting Online Unapproved Drug Sales The U.S. Food and Drug Administration (FDA) has issued a coordinated series of warning letters targeting companies marketing unapproved drug products online, signaling an intensified enforcement...
FDA Approves First Treatment to Reduce Risk of Acute Pancreatitis
FDA Approves First Treatment Proven to Reduce Acute Pancreatitis Risk in Severe HypertriglyceridemiaAn important example of the distinction between surrogate endpoints and clinical outcomes in drug development The U.S. Food and Drug Administration (FDA) has approved...
